NCT04209218 Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
| NCT ID | NCT04209218 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,988 participants |
| Start Date | 2020-04-07 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,988 participants in total. It began in 2020-04-07 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Surgery is the front-line therapy for non-small cell lung cancer (NSCLC) but postoperative complications remains high and patients' long-term outcome is still challenging. In addition to surgery, anesthetic management particularly intraoperative blood pressure management and use of dexamethasone may affect patients' early and long-term outcomes after surgery for NSCLC. This study aims to investigate the impact of intraoperative blood pressure management and dexamethasone administration on early and long-term outcomes in patients undergoing surgery for lung cancer.
Eligibility Criteria
Inclusion Criteria: * Aged \>50 years but \<90 years. * Diagnosed as resectable primary non-small cell lung cancer (stage IA-IIIA) and scheduled for radical surgery with an expected duration of \>2 hours. * Agree to participate in this study and sign the informed consent. Exclusion Criteria: * Clinical examinations suggest non-resectable lung cancer or patients scheduled for a biopsy surgery. * Recurrent or metastatic lung cancer. * History of cancer or complicated with cancer in other organs. * Long-term exposure to glucocorticoids or other immunosuppressant(s) due to autoimmune disease or organ transplantation. * Uncontrolled hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg); or requirement of vasopressors to maintain blood pressure. * Persistent atrial fibrillation, or acute cardiovascular events (acute coronary syndrome, stroke, or congestive heart failure) within 3 months. * Severe hepatic dysfunction (Child-Pugh C) or renal failure (requirement of renal replacement therapy). * Any other circumstances considered unsuitable for study participation by attending physicians or investigators.
Contact & Investigator
Dong-Xin Wang, MD, PhD
PRINCIPAL INVESTIGATOR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT04209218 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 90 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04209218 currently recruiting?
Yes, NCT04209218 is actively recruiting participants. Contact the research team at wangdongxin@hotmail.com for enrollment information.
Where is the NCT04209218 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT04209218 clinical trial?
NCT04209218 is sponsored by Peking University First Hospital. The principal investigator is Dong-Xin Wang, MD, PhD at Peking University First Hospital. The trial plans to enroll 1,988 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.